JP2021505172A5 - - Google Patents

Download PDF

Info

Publication number
JP2021505172A5
JP2021505172A5 JP2020531468A JP2020531468A JP2021505172A5 JP 2021505172 A5 JP2021505172 A5 JP 2021505172A5 JP 2020531468 A JP2020531468 A JP 2020531468A JP 2020531468 A JP2020531468 A JP 2020531468A JP 2021505172 A5 JP2021505172 A5 JP 2021505172A5
Authority
JP
Japan
Prior art keywords
donor
disease
cells
population
hematopoietic stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020531468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505172A (ja
Filing date
Publication date
Priority claimed from US15/834,017 external-priority patent/US10058573B1/en
Application filed filed Critical
Priority claimed from PCT/US2018/064335 external-priority patent/WO2019113375A2/en
Publication of JP2021505172A publication Critical patent/JP2021505172A/ja
Publication of JP2021505172A5 publication Critical patent/JP2021505172A5/ja
Priority to JP2023188499A priority Critical patent/JP2024023226A/ja
Pending legal-status Critical Current

Links

JP2020531468A 2017-12-06 2018-12-06 造血幹細胞及び前駆細胞を動員させるための投薬レジメン Pending JP2021505172A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023188499A JP2024023226A (ja) 2017-12-06 2023-11-02 造血幹細胞及び前駆細胞を動員させるための投薬レジメン

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US15/834,017 2017-12-06
US15/834,017 US10058573B1 (en) 2017-12-06 2017-12-06 Dosing regimens for the mobilization of hematopoietic stem cells
US201762596056P 2017-12-07 2017-12-07
US62/596,056 2017-12-07
US16/101,676 2018-08-13
US16/101,676 US20190167726A1 (en) 2017-12-06 2018-08-13 Dosing Regimens for the Mobilization of Hematopoietic Stem Cells
US201862753656P 2018-10-31 2018-10-31
US62/753,656 2018-10-31
US201862773954P 2018-11-30 2018-11-30
US62/773,954 2018-11-30
PCT/US2018/064335 WO2019113375A2 (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023188499A Division JP2024023226A (ja) 2017-12-06 2023-11-02 造血幹細胞及び前駆細胞を動員させるための投薬レジメン

Publications (2)

Publication Number Publication Date
JP2021505172A JP2021505172A (ja) 2021-02-18
JP2021505172A5 true JP2021505172A5 (https=) 2022-01-11

Family

ID=66749948

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020531468A Pending JP2021505172A (ja) 2017-12-06 2018-12-06 造血幹細胞及び前駆細胞を動員させるための投薬レジメン
JP2023188499A Pending JP2024023226A (ja) 2017-12-06 2023-11-02 造血幹細胞及び前駆細胞を動員させるための投薬レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023188499A Pending JP2024023226A (ja) 2017-12-06 2023-11-02 造血幹細胞及び前駆細胞を動員させるための投薬レジメン

Country Status (12)

Country Link
EP (1) EP3720494A2 (https=)
JP (2) JP2021505172A (https=)
KR (1) KR20200096942A (https=)
CN (1) CN111712262A (https=)
AU (1) AU2018378804B2 (https=)
BR (1) BR112020011186A2 (https=)
CA (1) CA3083783A1 (https=)
CO (1) CO2020007275A2 (https=)
IL (2) IL275077B2 (https=)
MX (2) MX2020005878A (https=)
SG (1) SG11202004913TA (https=)
WO (1) WO2019113375A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
EP4051298A1 (en) * 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
CA3176979A1 (en) * 2020-04-27 2021-11-04 Anthony Boitano Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2022197776A1 (en) * 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
CA3258771A1 (en) * 2022-06-10 2023-12-14 Gpcr Therapeutics, Inc. GPCR INHIBITORS AND THEIR USES

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5233044A (en) 1989-06-08 1993-08-03 Millipore Corporation Active esters for solid phase peptide synthesis
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US6447766B1 (en) 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
ES2210255T3 (es) 1993-06-08 2004-07-01 Smithkline Beecham Corporation Metodos para mejorar la actividad biologica de quimiocinas.
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
KR100463630B1 (ko) 1997-02-11 2005-05-25 말린크로트, 인코포레이티드 고상 펩티드 합성용 반응기 및 방법_
ES2156581T5 (es) 1998-03-30 2015-01-21 Northwest Biotherapeutics, Inc. Aplicaciones terapéuticas y diagnósticas basadas en el papel del gen CXCR-4 en la tumorigénesis
AP1654A (en) 1999-03-24 2006-09-01 Anormed Inc Chemokine receptor binding heterocyclic compounds.
AU2334301A (en) 1999-12-17 2001-06-25 Anormed Inc. Chemokine receptor binding heterocyclic compounds
EP1286684B1 (en) 2000-05-09 2004-04-28 The University Of British Columbia use of cxcr4 antagonists for treating autoimmune diseases and cancer
MXPA02012067A (es) 2000-06-05 2004-08-19 Univ Columbia Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico.
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
DK1411918T3 (da) * 2001-07-31 2012-04-23 Genzyme Global S A R L Fremgangsmåder til at mobilisere progenitor/stamceller
JP5170934B2 (ja) 2001-08-16 2013-03-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 改良ｄｎａリポフェクションならびに／または徐放性プロドラッグおよび薬物療法のための試薬の合成と使用
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
US20070033666A1 (en) 2005-06-24 2007-02-08 Harris Reuben S Using cytosine deaminases to diminish retroelement transfer from pigs to humans
WO2007047882A2 (en) * 2005-10-18 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Combination of cxcr4 antagonist and morphogen to increase angiogenesis
ES2582091T3 (es) 2005-10-18 2016-09-09 Precision Biosciences Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
US20100003224A1 (en) * 2006-08-02 2010-01-07 Genzyme Corporation Combination Therapy
CN101500595A (zh) * 2006-08-07 2009-08-05 健赞股份有限公司 组合治疗
EP1995316A1 (de) 2007-05-25 2008-11-26 Qiagen GmbH Verfahren zur schonenden Zellaufreinigung, Zellgewinnung und Transfektion von Zellen
EP2009095A1 (en) 2007-06-28 2008-12-31 Innovalor AG Method of generating glucose-responsive cells
EP2215223B1 (en) 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EP2270025A1 (en) 2009-06-29 2011-01-05 Centre National pour la Recherche Scientifique (CNRS) Solid phase peptide synthesis of peptide alcohols
EP2533629B1 (en) 2010-02-11 2018-11-28 Recombinetics, Inc. Methods and materials for producing transgenic artiodactyls
MX363013B (es) 2011-02-25 2019-03-04 Recombinetics Inc Animales genéticamente modificados y métodos para su obtención.
US9388212B2 (en) 2013-02-21 2016-07-12 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Solid phase peptide synthesis via side chain attachment
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP2946008A4 (en) * 2013-01-15 2016-07-20 Ohio State Innovation Foundation PROCESS FOR MOBILIZING HEMATOPOETIC STEM CELLS
KR102503695B1 (ko) * 2013-02-28 2023-02-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 동원하기 위한 방법 및 조성물
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
EP3419617A4 (en) * 2016-02-26 2019-10-23 President and Fellows of Harvard College HIGH GRADE TRANSPLANTABLE HEMATOPOETIC STEM CELLS
WO2018085574A2 (en) * 2016-11-02 2018-05-11 Washington University Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof
US10058573B1 (en) * 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells

Similar Documents

Publication Publication Date Title
JP2021505172A5 (https=)
Jurewicz et al. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes
US8685728B2 (en) Kit containing stem cells and cytokines for use in attenuating immune responses
Lu et al. Unmanipulated haploidentical hematopoietic stem cell transplantation achieved outcomes comparable with matched unrelated donor transplantation in young acquired severe aplastic anemia
Bacigalupo Alternative donor transplants for severe aplastic anemia
Hong et al. Favorable outcome of post-transplantation cyclophosphamide haploidentical peripheral blood stem cell transplantation with targeted busulfan-based myeloablative conditioning using intensive pharmacokinetic monitoring in pediatric patients
Luo et al. CMV infection and CMV-specific immune reconstitution following haploidentical stem cell transplantation: an update
Picardi et al. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma
Jaiswal et al. Higher CD45RA+ Regulatory T cells in the graft improves outcome in younger patients undergoing T cell–replete haploidentical transplantation: where donor age matters
Murphy et al. Mesenchymal stem cell therapy to promote corneal allograft survival: current status and pathway to clinical translation
JP2021502824A5 (https=)
Ringdén et al. Mesenchymal stromal cells in pediatric hematopoietic cell transplantation a review and a pilot study in children treated with decidua stromal cells for acute graft-versus-host disease
Sodani et al. T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients
Gong et al. Alternative transplantation with post-transplantation cyclophosphamide in aplastic anemia: a retrospective report from the BMF-WG of Hunan Province, China
Lin et al. Role of memory T cells and perspectives for intervention in organ transplantation
Fu et al. Reduced intensity conditioning and co-transplantation of unrelated peripheral stem cells combined with umbilical cord mesenchymal stem/stroma cells for young patients with refractory severe aplastic anemia
Fu et al. Recombinant human thrombopoietin promotes platelet engraftment in severe aplastic anemia patients following treatment with haploid hematopoietic stem cell transplantation using modified post-transplantation cyclophosphamide
Wu et al. Prospective study of a modified post-transplantation cyclophosphamide regimen for severe aplastic anemia patients with HLA-haploidentical transplantation
Leung et al. Haematopoietic stem cell transplantation: current concepts and novel therapeutic strategies
Liang et al. Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy
Yolcu et al. Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease
Dong et al. CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin
Quintero et al. Haploidentical hematopoietic stem cell transplantation in pediatric patients with acquired hypocellular bone marrow failure
Mahadeo et al. A reduced-toxicity regimen is associated with durable engraftment and clinical cure of nonmalignant genetic diseases among children undergoing blood and marrow transplantation with an HLA-matched related donor
JP2021503008A5 (https=)